Prognosis of critically ill cirrhotic versus non-cirrhotic patients: a comprehensive score-matched study

BMC Anesthesiology

Table 3 SOFA-matched patient demographic data and clinical characteristics according to cirrhosis and non-cirrhosis

	Total (n = 110)	Cirrhosis (n = 55)	Non-cirrhosis (n = 55)	p-value
Age (years)	65.0 ± 1.4	61.1 ± 2.0	68.9 ± 2.0	0.006
Male/Female	79/31	40/15	39/16	NS(0.832)
Length of ICU stay (days)	14 ± 1	11 ± 1	18 ± 2	0.007
Length of Hospital stay (days)	31 ± 2	32 ± 4	31 ± 3	NS(0.843)
Body weight on ICU admission (kg)	60 ± 1	64 ± 2	56 ± 2	0.001
GCS, ICU first day (points)	10 ± 0	11 ± 1	8 ± 1	0.005
MAP, ICU admission (mmHg)	78 ± 2	83 ± 2	73 ± 2	0.002
Serum Creatinine, ICU first day (mg/dl)	2.4 ± 0.2	1.8 ± 0.2	3.0 ± 0.3	0.004
Arterial HCO₃ ⁻, ICU first day	21 ± 1	20 ± 1	21 ± 1	NS(0.458)
Serum Sodium, ICU first day (mg/dl)	137 ± 1	138 ± 1	137 ± 1	NS(0.282)
Bilirubin, ICU first day (mg/dl)	5.8 ± 0.8	9.6 ± 1.5	1.9 ± 0.4	<0.001
Albumin, ICU first day (g/l)	2.4 ± 0.1	2.5 ± 0.1	2.3 ± 0.1	0.016
Blood Sugar, ICU first day (mg/dl)	160 ± 8	159 ± 12	161 ± 11	NS(0.899)
Hemoglobin, ICU first day (g/dl)	9.7 ± 0.2	9.3 ± 0.3	10.0 ± 0.3	NS(0.134)
Platelets, ICU first day (×10³/μL)	127.3 ± 10.1	85.8 ± 8.1	168.8 ± 16.9	<0.001
Leukocytes, ICU first day (×10³/μL)	13.9 ± 0.8	12.9 ± 1.3	14.9 ± 1.0	NS(0.224)
PaO₂/FiO₂, ICU first day(mmHg)	256 ± 13	270 ± 16	243 ± 19	NS(0.299)
Shock(%)	39 (35.5)	9 (16.3)	30 (54.5)	<0.001
Hospital mortality (%)	71(64.5)	34 (61.8)	37 (67.3)	NS(0.550)
Score systems
APACHE III, ICU first day(mean ± SE)	86.5 ± 2.8	81.1 ± 4.2	91.9 ± 3.7	NS(0.058)
SOFA, ICU first day(mean ± SE)	10.0 ± 0.3	10.0 ± 0.5	10.0 ± 0.3	NS(0.927)
RIFLE, ICU first day(mean ± SE)	1.6 ± 0.1	1.4 ± 0.2	1.9 ± 0.2	0.041

Abbreviation: NS, not significant; ICU, intensive care unit; SE, standard error; GCS, Glasgow coma scale; MAP, mean arterial pressure; PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, sequential organ failure assessment; RIFLE, risk of renal failure, injury to the kidney, failure of kidney function, loss of kidney function, and end-stage renal failure.

ISSN: 1471-2253